11 results for author:"Harrison C.N." in Literature citations
Results Customize
› Repeat search in UniProtKB (1)
| JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Godfrey A.L., Chen E., Pagano F., Ortmann C.A., Silber Y., Bellosillo B., Guglielmelli P., Harrison C.N., Reilly J.T., Stegelmann F. et al. Blood 120:2704-2707(2012) · Mapped (6) |
| The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Jones A.V., Campbell P.J., Beer P.A., Schnittger S., Vannucchi A.M., Zoi K., Percy M.J., McMullin M.F., Scott L.M., Tapper W. et al. Blood 115:4517-4523(2010) · Mapped (9) |
| Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Beer P.A., Delhommeau F., LeCouedic J.P., Dawson M.A., Chen E., Bareford D., Kusec R., McMullin M.F., Harrison C.N., Vannucchi A.M. et al. Blood 115:2891-2900(2010) · Mapped (6) |
| Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Fourouclas N., Li J., Gilby D.C., Campbell P.J., Beer P.A., Boyd E.M., Goodeve A.C., Bareford D., Harrison C.N., Reilly J.T. et al. Haematologica 93:1635-1644(2008) · Mapped (5) |
| MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Beer P.A., Campbell P.J., Scott L.M., Bench A.J., Erber W.N., Bareford D., Wilkins B.S., Reilly J.T., Hasselbalch H.C., Bowman R. et al. Blood 112:141-149(2008) · Mapped (3) |
| The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Percy M.J., Scott L.M., Erber W.N., Harrison C.N., Reilly J.T., Jones F.G., Green A.R., McMullin M.F. Haematologica 92:1607-1614(2007) · Mapped (6) |
| JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A., Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N. et al. N. Engl. J. Med. 356:459-468(2007) · UniProtKB (1) · Mapped (5) |
| Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Campbell P.J., Baxter E.J., Beer P.A., Scott L.M., Bench A.J., Huntly B.J., Erber W.N., Kusec R., Larsen T.S., Giraudier S. et al. Blood 108:3548-3555(2006) · Mapped (6) |
| Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. The United Kingdom myeloproliferative disorders study group, The medical research council adult leukaemia working party, The Australasian leukaemia and lymphoma group Lancet 366:1945-1953(2005) · UniProtKB (1) |
| V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Campbell P.J., Griesshammer M., Dohner K., Dohner H., Kusec R., Hasselbalch H.C., Larsen T.S., Pallisgaard N., Giraudier S., Le Bousse-Kerdiles M.C. et al. Blood 107:2098-2100(2006) · Mapped (6) |
| Lack of pathogenic mutations in the 5'-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemia. Allen A.J., Gale R.E., Harrison C.N., Machin S.J., Linch D.C. Eur. J. Haematol. 67:232-237(2001) · Mapped (8) |